Why Do Doctors Dismiss PCOS Symptoms?

Why Do Doctors Dismiss PCOS Symptoms?

Yes, dismissal is common — and documented. Studies show the average woman with PCOS waits two or more years and consults multiple clinicians before receiving a correct diagnosis. The core reasons are symptom overlap with other conditions, inconsistent use of diagnostic criteria, and a cultural tendency to frame irregular periods, acne, and weight changes as lifestyle problems rather than endocrine disease. The exception: women who present with the classic triad (irregular cycles + hyperandrogenism + polycystic ovaries on ultrasound) are diagnosed faster, though even they face delays.

The Diagnostic Gap: Why PCOS Is So Often Missed

Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, affecting an estimated 8–13% of this population worldwide (Teede et al., Human Reproduction Update 2018; PMID: 29889940). Despite that prevalence, a large patient survey published in Fertility and Sterility found that 34% of women with PCOS were initially told nothing was wrong, and many received diagnoses for anxiety, thyroid disease, or depression before PCOS was considered (Gibson-Helm et al., Fertility and Sterility 2017; PMID: 27916205).

Several structural factors explain this gap:

• Inconsistent diagnostic criteria. Clinicians may use Rotterdam criteria (2003), the older NIH 1990 criteria, or the Androgen Excess Society guidelines — each produces a different prevalence estimate and misses different phenotypes. A woman with irregular cycles and elevated androgens but no ultrasound findings (Rotterdam phenotype C) may be told she doesn't have PCOS under stricter NIH criteria.
• Symptom normalization. Irregular periods are frequently attributed to stress. Hirsutism is dismissed as a cosmetic concern. Acne is handed off to dermatology. No single symptom on its own triggers an endocrine workup.
• Time pressure in primary care. A 15-minute appointment rarely allows a full hormonal history, and PCOS requires integrating menstrual, metabolic, and androgenic data together.
• Weight bias. Clinicians often attribute all of a patient's symptoms to body weight, when in reality insulin resistance and androgen excess are driving both the weight and the other symptoms simultaneously.
• Lean PCOS is frequently invisible. Roughly 20–30% of women with PCOS have a normal BMI (Lim et al., Journal of Clinical Endocrinology & Metabolism 2012; PMID: 22419718). When a clinician's mental model of PCOS is anchored to obesity, these women are systematically screened out before a workup begins.

If you feel your concerns are being dismissed, you are not alone — and the research into why doctors dismiss perimenopause symptoms reveals the same pattern of normalization applied to women's hormonal health more broadly.

Key Biomarkers That Get Overlooked in PCOS Workups

Even when PCOS is suspected, labs are often incomplete. A standard workup may check LH, FSH, and total testosterone — and stop there. But PCOS is a metabolic-endocrine condition with a much wider biomarker footprint:

The relationship between SHBG and PCOS is particularly under-discussed in primary care. Low SHBG is both a marker and a mechanism — when insulin suppresses hepatic SHBG production, more free testosterone circulates, worsening acne, hirsutism, and anovulation. You can read more about what happens to SHBG levels in PCOS and why it's one of the first markers to trend before LH or FSH become visibly abnormal.

The Insulin–Androgen Axis: The Mechanism Most Clinicians Don't Explain

Understanding PCOS dismissal isn't only about physician behavior — it also reflects how poorly the insulin–androgen axis is taught. In most clinical training, PCOS is introduced as a reproductive disorder. The metabolic pathology is often treated as secondary.

The mechanism is actually central: hyperinsulinemia stimulates theca cells in the ovary to overproduce androgens via upregulation of cytochrome P450c17α enzyme activity. Simultaneously, insulin suppresses hepatic SHBG synthesis, amplifying the effect of already-elevated free testosterone. This creates a self-reinforcing loop: high androgens impair follicular maturation, leading to anovulation; anovulation leads to progesterone deficiency; and unopposed estrogen further disrupts the HPG axis.

A landmark trial by Nestler et al. in the New England Journal of Medicine showed that reducing insulin with metformin restored ovulation in women with PCOS who had not responded to clomiphene — directly demonstrating that the insulin axis, not just LH/FSH dysregulation, drives anovulation (Nestler et al., NEJM 1998; PMID: 9435325). This foundational finding is over two decades old, yet many primary care visits for PCOS still don't include fasting insulin or HOMA-IR.

What a Complete PCOS Protocol Should Look Like

Once the correct biomarkers are in view, management becomes far more targeted. A symptom-to-protocol framework looks like this:

Step 1 — Confirm phenotype. Rotterdam criteria require 2 of 3: oligo-anovulation, clinical or biochemical hyperandrogenism, polycystic ovaries on ultrasound. Identifying the phenotype (A, B, C, or D) guides how aggressively to treat insulin resistance.

Step 2 — Quantify insulin resistance. Order fasting insulin, fasting glucose, and calculate HOMA-IR (fasting insulin × fasting glucose ÷ 405). A HOMA-IR above 2.0 warrants intervention regardless of whether fasting glucose is technically "normal."

Step 3 — Address androgen drivers. Free testosterone, DHEA-S, and SHBG together reveal whether the excess is primarily ovarian, adrenal, or mixed. Adrenal-dominant PCOS (elevated DHEA-S, relatively normal LH:FSH) responds differently to both pharmacological and nutritional interventions.

Step 4 — Evaluate nutrient cofactors. Several micronutrients directly modulate insulin signaling and ovarian steroidogenesis:

• Inositol (myo-inositol + D-chiro-inositol at a 40:1 ratio): A meta-analysis of 13 RCTs found combined inositol significantly reduced fasting insulin, free testosterone, and improved menstrual regularity in women with PCOS compared to placebo (Unfer et al., Gynecological Endocrinology 2017). The effect size for insulin reduction was comparable to low-dose metformin in direct head-to-head trials.
• Chromium: Chromium picolinate at 200 µg/day improved insulin sensitivity markers in a randomized controlled trial in women with PCOS (Lydic et al., Fertility and Sterility 2006; PMID: 16413892). Chromium enhances insulin receptor signaling by potentiating the activity of chromodulin, a low-molecular-weight chromium-binding oligopeptide. If you're curious about the broader picture of chromium deficiency and its symptoms and supplement strategies, that article walks through the functional-medicine perspective in detail.
• Zinc: Zinc at 50 mg/day over 8 weeks reduced hirsutism scores, fasting insulin, and total testosterone in a double-blind RCT of 48 women with PCOS (Jamilian et al., Journal of Trace Elements in Medicine and Biology 2016; PMID: 27261539). Zinc inhibits 5-alpha reductase, the enzyme that converts testosterone to the more potent dihydrotestosterone (DHT) at the hair follicle and skin.
• Vitamin D: Vitamin D deficiency is found in up to 85% of women with PCOS in some cohorts. Supplementation with 50,000 IU/week for 8 weeks improved menstrual regularity and reduced HOMA-IR in a randomized trial (Rahimi et al., Journal of Clinical Endocrinology & Metabolism 2018).
• Omega-3 fatty acids (EPA/DHA): High-dose omega-3 (3.6 g/day EPA+DHA for 8 weeks) significantly lowered serum triglycerides, total testosterone, and LH levels versus placebo in a 2012 RCT of women with PCOS (Khani et al., Journal of Research in Medical Sciences 2012).

Step 5 — Lifestyle co-interventions with documented PCOS effect sizes. A low-glycemic index diet reduces androgen levels and improves insulin sensitivity independently of weight loss — a 12-week crossover study showed significantly lower free androgen index on the low-GI diet compared to a healthy conventional diet (Marsh et al., American Journal of Clinical Nutrition 2010; PMID: 20107195). Resistance training 2–3×/week improves GLUT4 translocation in skeletal muscle, reducing the insulin burden on the ovary even without significant scale movement.

For women exploring options beyond pharmaceuticals, what helps with PCOS symptoms without hormones is a useful companion read that covers both lifestyle and evidence-backed supplement approaches in more depth.

Botanical Interventions With Clinical Evidence in PCOS

Beyond micronutrients, several botanicals have published RCT data in PCOS specifically:

Maca (Lepidium meyenii): A small but well-controlled trial showed improvements in LH:FSH ratio and subjective hormonal symptoms after 12 weeks of maca supplementation. Dosing matters significantly — for a breakdown of how much maca to take for PCOS, including the doses studied in trials, see our dedicated guide.

Ashwagandha (KSM-66, 600 mg/day): Cortisol dysregulation is common in PCOS, particularly in the adrenal phenotype. Ashwagandha at 600 mg/day reduced serum cortisol by 27.9% over 60 days in a double-blind RCT of chronically stressed adults (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). Elevated cortisol independently stimulates adrenal androgen production (DHEA-S), making cortisol management a legitimate upstream target in adrenal-pattern PCOS.

Berberine: Berberine at 500 mg three times daily showed comparable effects to metformin on fasting insulin, HOMA-IR, and menstrual frequency in a randomized trial of 89 women with PCOS (An et al., Fertility and Sterility 2014). Its mechanism — AMPK activation — parallels metformin's but operates via a distinct pathway, making it a commonly studied alternative for women who cannot tolerate metformin's GI side effects.

What This Means for Your Formula

A personalized formula for PCOS-pattern findings looks very different from a generic women's multivitamin. The key levers are insulin sensitization, androgen modulation, and cortisol regulation — and the specific ingredients that move those markers are dosed at clinical ranges, not token amounts.

Ones includes several ingredients directly relevant to the PCOS biomarker landscape:

• Zinc (dosed at clinically relevant amounts): Ones formulas include zinc calibrated to your baseline lab status — important because excess zinc suppresses copper, and the therapeutic window for hirsutism and 5-alpha reductase inhibition requires accurate dosing rather than one-size supplementation. For reference, the Jamilian 2016 RCT used 50 mg/day — higher than most multivitamins provide.
• Omega-3 (EPA/DHA): Ones includes EPA/DHA at doses designed to reach anti-inflammatory thresholds relevant to androgen and triglyceride reduction, not the sub-gram amounts common in standard fish oil capsules.
• KSM-66 Ashwagandha at 600 mg: For women whose PCOS workup shows elevated DHEA-S alongside high perceived stress or elevated morning cortisol, the Adrenal Support blend within Ones formulas — alongside KSM-66 at the clinically studied dose — directly targets the cortisol–DHEA axis upstream of ovarian androgen excess.

Because Ones analyzes blood work and health history together, it can distinguish between insulin-dominant, androgen-dominant, and adrenal-pattern PCOS presentations and build a formula that addresses the specific drivers your labs reveal — rather than defaulting to a generic hormonal support stack.

Key Takeaways

• PCOS affects 8–13% of reproductive-age women but takes an average of 2+ years to diagnose, driven by symptom normalization, inconsistent diagnostic criteria, and weight bias.
• A complete workup goes beyond LH/FSH and total testosterone — fasting insulin, HOMA-IR, SHBG, free testosterone, DHEA-S, AMH, and 25-OH vitamin D are all clinically relevant.
• Lean PCOS (normal BMI) is particularly under-recognized; 20–30% of PCOS patients fall into this category and are routinely screened out before a workup begins.
• The insulin–androgen axis is the central mechanism: hyperinsulinemia drives ovarian androgen overproduction and suppresses SHBG, amplifying androgenic symptoms even when total testosterone is borderline.
• Evidence-backed micronutrients — chromium, zinc, vitamin D, omega-3, and inositol — each have RCT data specifically in PCOS populations at defined doses.
• A personalized formula calibrated to your specific PCOS phenotype and lab results is meaningfully different from a standard women's supplement — the same ingredient at the wrong dose may be ineffective or counterproductive.